title: Inducing labor with a sustained-release PGE2 vaginal insert. Experience at a community hospital.
abstract: OBJECTIVE
  To determine the safety of initiating labor using a sustained-release prostaglandin E2 (PGE2) vaginal insert at a nonuniversity-based community hospital.
  
  
  METHODS
  Data were compiled from a chart review of all cases in which the insert (Cervidil) was used during a 16-month period. Continuous uterine activity and fetal heart rate (FHR) tracings were evaluated for 12 hours after dosing. The onset of regular uterine contractions or of active labor and the reason for any premature removal of the insert were sought.
  
  
  RESULTS
  Regular contractions ensued in 62 (35.8%) of 173 pregnancies. Primary reasons for removal of the insert in 59 (34.1%) cases were active labor (38), ruptured membranes (11), uterine hyperstimulation (7) and a nonreassuring FHR tracing. The average time from insertion until premature removal was 5.7 +/- 1.3 (SD) hours (95% confidence interval, 3.3-8.2). The insert fell out in nine (5.2%) cases. Cesarean delivery for failed labor induction was necessary in five (2.9%) cases. All immediate neonatal outcomes were reassuring. Following inservice training, nurses were capable of inserting and removing the insert.
  
  
  CONCLUSIONS
  This PGE2 vaginal insert, administered and removed by attending nurses, is associated with very low rates of uterine hyperstimulation and failed induction. Premature removal of the insert occurred in 34.1% of cases.
authors.affiliation: Department of Obstetrics and Gynecology, Columbia Presbyterian Hospital, Oklahoma City, Oklahoma, USA.
authors.forename: F C
authors.initials: FC
authors.lastname: Blair
authors.forename: S A
authors.initials: SA
authors.lastname: Tassone
authors.forename: C R
authors.initials: CR
authors.lastname: Pearman
authors.forename: M B
authors.initials: MB
authors.lastname: St Cyr
authors.forename: W F
authors.initials: WF
authors.lastname: Rayburn
mesh_terms: D000282:Administration, Intravaginal; D000293:Adolescent; D000328:Adult; D002585:Cesarean Section; D015232:Dinoprostone / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005322:Premature Rupture of Fetal Membranes; D006340:Heart Rate, Fetal; D006764:Hospitals, Community; D006801:Humans; D007751:Labor, Induced; D007743:Labor, Obstetric; D011247:Pregnancy; D013997:Time Factors; D016896:Treatment Outcome; D014590:Uterine Contraction
chemical_list: D015232:Dinoprostone